Cargando…

Cleavage‐Responsive Biofactory T Cells Suppress Infectious Diseases‐Associated Hypercytokinemia

Severe infectious diseases, such as coronavirus disease 2019 (COVID‐19), can induce hypercytokinemia and multiple organ failure. In spite of the growing demand for peptide therapeutics against infectious diseases, current small molecule‐based strategies still require frequent administration due to l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyelim, Son, Boram, Seo, Eun U, Kwon, Miji, Ahn, June Hong, Shin, Heungsoo, Song, Gyu Yong, Park, Eun Ji, Na, Dong Hee, Cho, Seung‐Woo, Kim, Hong Nam, Park, Hee Ho, Lee, Wonhwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475519/ https://www.ncbi.nlm.nih.gov/pubmed/35751470 http://dx.doi.org/10.1002/advs.202201883

Ejemplares similares

Cleavage‐Responsive Biofactory T Cells Suppress Infectious Diseases‐Associated Hypercytokinemia (Adv. Sci. 26/2022)
por: Kim, Hyelim, et al.
Publicado: (2022)

COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm
por: Lee, Wonhwa, et al.
Publicado: (2020)

Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for severe acute respiratory syndrome coronavirus 2 patients
por: Choi, Eun Young, et al.
Publicado: (2020)

Nanodiamond as a Cytokine Sponge in Infectious Diseases
por: Yoo, Wonbeak, et al.
Publicado: (2022)

Bioinspired DNase‐I‐Coated Melanin‐Like Nanospheres for Modulation of Infection‐Associated NETosis Dysregulation
por: Park, Hee Ho, et al.
Publicado: (2020)

Bioinspired DNase‐I‐Coated Melanin‐Like Nanospheres for Modulation of Infection‐Associated NETosis Dysregulation
por: Park, Hee Ho, et al.
Publicado: (2021)

Streptomyces: The biofactory of secondary metabolites
por: Alam, Khorshed, et al.
Publicado: (2022)

Continuous hemodiafiltration for hypercytokinemia in tumor lysis syndrome
por: Nakamura, M, et al.
Publicado: (2005)

Hypercytokinemia and Pathogen–Host Interaction in COVID-19
por: Badawi, Alaa
Publicado: (2020)

Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm
por: Lee, Yun Young, et al.
Publicado: (2021)

PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives ameliorate SARS-CoV-2-mediated hyper-inflammatory responses
por: Park, Hee Ho, et al.
Publicado: (2021)

Rhodococcus as Biofactories for Microbial Oil Production
por: Alvarez, Héctor M., et al.
Publicado: (2021)

Current and future developments in the treatment of virus-induced hypercytokinemia
por: Wong, Jonathan P, et al.
Publicado: (2017)

Lung-selective 25-hydroxycholesterol nanotherapeutics as a suppressor of COVID-19-associated cytokine storm
por: Kim, Hyelim, et al.
Publicado: (2021)

Stramenopile microalgae as “green biofactories” for recombinant protein production
por: de Grahl, Imke, et al.
Publicado: (2021)

Biomass from microalgae: the potential of domestication towards sustainable biofactories
por: Benedetti, Manuel, et al.
Publicado: (2018)

Plant-Derived Cell-Free Biofactories for the Production of Secondary Metabolites
por: Buntru, Matthias, et al.
Publicado: (2022)

Microalgal Cell Biofactory—Therapeutic, Nutraceutical and Functional Food Applications
por: Kiran, Boda Ravi, et al.
Publicado: (2021)

Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients
por: Burgos-Blasco, Barbara, et al.
Publicado: (2020)

Interferon signaling and hypercytokinemia-related gene expression in the blood of antidepressant non-responders
por: Yamagata, Hirotaka, et al.
Publicado: (2023)

Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics
por: Zhong, Huahua, et al.
Publicado: (2023)

Protein-Based Nanoparticles as Drug Delivery Systems
por: Hong, Seyoung, et al.
Publicado: (2020)

Comparative Evaluation of Recombinant Protein Production in Different Biofactories: The Green Perspective
por: Merlin, Matilde, et al.
Publicado: (2014)

Comparative analysis of different biofactories for the production of a major diabetes autoantigen
por: Avesani, Linda, et al.
Publicado: (2013)

Mushrooms and Truffles: Historical Biofactories for Complementary Medicine in Africa and in the Middle East
por: El Enshasy, Hesham, et al.
Publicado: (2013)

Stone Fruit as Biofactories of Phytochemicals With Potential Roles in Human Nutrition and Health
por: Lara, María Valeria, et al.
Publicado: (2020)

Cordyceps – A traditional Chinese medicine and another fungal therapeutic biofactory?
por: Paterson, R. Russell M.
Publicado: (2008)

Production of Potyvirus-Derived Nanoparticles Decorated with a Nanobody in Biofactory Plants
por: Martí, Maricarmen, et al.
Publicado: (2022)

Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19
por: England, Corbin, et al.
Publicado: (2023)

COVID-19 Severity Correlates with Weaker T-Cell Immunity, Hypercytokinemia, and Lung Epithelium Injury
por: Wang, Zhongfang, et al.
Publicado: (2020)

Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice
por: Westover, Jonna B., et al.
Publicado: (2019)

The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19
por: Guo, Jing, et al.
Publicado: (2020)

Rice Seeds as Biofactories of Rationally Designed and Cell-Penetrating Antifungal PAF Peptides
por: Bundó, Mireia, et al.
Publicado: (2019)

Gut Biofactory—Neurocompetent Metabolites within the Gastrointestinal Tract. A Scoping Review
por: Skonieczna-Żydecka, Karolina, et al.
Publicado: (2020)

Plants as Biofactories to Produce Food, Medicines, and Materials for a True Green Revolution
por: Zarrelli, Armando
Publicado: (2022)

Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
por: Bermejo-Martin, Jesus F, et al.
Publicado: (2009)

Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase‐4 inhibitor vildagliptin
por: Anno, Takatoshi, et al.
Publicado: (2018)

GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro
por: Hong, Kyung Soo, et al.
Publicado: (2020)

Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu, Korea
por: Jang, Jong Geol, et al.
Publicado: (2020)

Delta-secretase cleavage of Tau mediates its pathology and propagation in Alzheimer’s disease
por: Kang, Seong Su, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_62nbnar9g6jbmvm8naltuq1nad